Bastien Cabarrou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bastien Cabarrou has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra Martinez
Department of Surgical Oncology, Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole, Toulouse, France
3 shared publications - Gwenaël Ferron
Department of Surgical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
3 shared publications - Martina Aida Angeles
Universitat Autònoma de Barcelona, Vall d'Hebron Barcelona Hospital Campus, Gynecologic Oncology Unit, Barcelona, Spain
3 shared publications - Agnieszka Rychlik
National Research Institute of Oncology, Department of Gynecologic Oncology, Warsaw, Poland
2 shared publications - Alicia Hernandez
Gynecology Department, La Paz University Hospital, Madrid, Spain
2 shared publications - Antonio Gil-Moreno
Gynecologic Oncology Unit, Department of Gynecology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain
2 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by Wiley in British Journal of Clinical Pharmacology
Integrated evaluation of pharmacokinetics and pharmacogenomics of sunitinib and pazopanib in patients with metastatic renal carcinoma
Aim: Sunitinib and pazopanib are anti‐angiogenic tyrosine kinase inhibitors (TKIs) used for metastatic renal cancer, with substantial interindividual variability in drug response. This study aimed to explore factors explaining this variability. Methods: Pharmacokinetics (PK) and pharmacogenomics (PG) data from 47 patients enrolled in the SUP‐R clinical trial (NCT02555748) were analysed retrospectively (32 treated with sunitinib, 15 with pazopanib). Plasma concentrations measured during the first two treatment cycles were analysed using a non‐linear mixed effects model. Exploratory analyses of factors influencing drug exposure, toxicity and efficacy were conducted, including a PG investigation of drug disposition, and target genes and baseline circulating microRNA levels. No correction for multiple comparisons was applied. Results: The PK models adequately described plasma concentration over time in the cohort. Patients experiencing severe toxicity (≥ Grade 3, CTCAE) showed reduced apparent sunitinib clearance (median 24.3 L/h [11.1–45.7] vs . 32.4 L/h [16.6–90.6], p = 0.006). Responders were more exposed to sunitinib and active metabolite SU12662 (observed C trough,ss = 140.1 ng/mL [43.2–209.5] vs . 89.5 ng/mL [4.3–230.7], p = 0.036); similar trends were observed with pazopanib, though limited events (3 responders/10 evaluable) precluded definitive interpretation. Carriers of at least one variant ABCB1 c.1199G>A allele were more likely to respond to TKI treatment (odd‐ratio = 10.8, 95% confidence interval [1.7–69.9], p = 0.012). Conclusion: This study assessed the exposure‐response relationships of both drugs and identified potential factors to consider in case of toxicity or treatment failure.
- 16 November 2026
- Published by Wiley in British Journal of Clinical Pharmacology
Open AccessIntegrated evaluation of pharmacokinetics and pharmacogenomics of sunitinib and pazopanib in patients with metastatic renal carcinoma
Aim: Sunitinib and pazopanib are anti‐angiogenic tyrosine kinase inhibitors (TKIs) used for metastatic renal cancer, with substantial interindividual variability in drug response. This study aimed to explore factors explaining this variability. Methods: Pharmacokinetics (PK) and pharmacogenomics (PG) data from 47 patients enrolled in the SUP‐R clinical trial (NCT02555748) were analysed retrospectively (32 treated with sunitinib, 15 with pazopanib). Plasma concentrations measured during the first two treatment cycles were analysed using a non‐linear mixed effects model. Exploratory analyses of factors influencing drug exposure, toxicity and efficacy were conducted, including a PG investigation of drug disposition, and target genes and baseline circulating microRNA levels. No correction for multiple comparisons was applied. Results: The PK models adequately described plasma concentration over time in the cohort. Patients experiencing severe toxicity (≥ Grade 3, CTCAE) showed reduced apparent sunitinib clearance (median 24.3 L/h [11.1–45.7] vs . 32.4 L/h [16.6–90.6], p = 0.006). Responders were more exposed to sunitinib and active metabolite SU12662 (observed C trough,ss = 140.1 ng/mL [43.2–209.5] vs . 89.5 ng/mL [4.3–230.7], p = 0.036); similar trends were observed with pazopanib, though limited events (3 responders/10 evaluable) precluded definitive interpretation. Carriers of at least one variant ABCB1 c.1199G>A allele were more likely to respond to TKI treatment (odd‐ratio = 10.8, 95% confidence interval [1.7–69.9], p = 0.012). Conclusion: This study assessed the exposure‐response relationships of both drugs and identified potential factors to consider in case of toxicity or treatment failure.
- Open Access
- 7 October 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (11)
Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression
Background: The management of oligometastatic breast cancer (OMBC) remains controversial, particularly regarding selection for local ablative treatment (LAT). In HR+/HER2− OMBC, where prolonged survival is often the case, improved stratification and characterization of progression may guide treatment. We aimed to define prognostic subsets, assess the contribution of Modern-Imaging-Methods (MIMs; 18F-FDG-PET/CT or WB-MRI) to LAT selection, and describe progression after first-line therapy in these subgroups of patients. Materials and Methods: All consecutive patients with HR+/HER2− OMBC treated at our institution between 2012 and 2020 were included. OMBC was defined as ≤5 metastases. Prognostic factors, including biological subtype, anatomical distribution, imaging modality, and LAT, were evaluated for overall and progression-free survival (OS, PFS). Results: Among 145 patients (median follow-up 82.8 months), median OS and PFS were, respectively, 81.1 and 26.5 months. Luminal-A-like subtypes, absence of liver metastases, and use of MIMs independently predicted better survival. LAT improved PFS (hazard ratio [HR] = 0.52; 95% CI: 0.29-0.91, P = .0233) and showed a trend toward longer OS. In patients staged with MIMs, LAT significantly improved both OS (HR = 0.29; 95% CI: 0.12-0.73, P = .008) and PFS (HR = 0.40; 95% CI: 0.21-0.77, P = .0064). After first-line systemic therapy, only 18% developed polymetastatic progression. Conclusion: In HR+/HER2− OMBC, 3 actionable considerations emerge: staging must incorporate modern imaging to accurately define metastatic burden; LAT may be considered in selected patients with low-grade disease, absence of liver metastases, and long disease-free interval; in oligoprogression after first-line therapy, LAT should be re-evaluated within a multidisciplinary setting. These data offer pragmatic benchmarks to individualize treatment while awaiting definitive randomized evidence.
- 7 October 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (11)
Open AccessHormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression
Background: The management of oligometastatic breast cancer (OMBC) remains controversial, particularly regarding selection for local ablative treatment (LAT). In HR+/HER2− OMBC, where prolonged survival is often the case, improved stratification and characterization of progression may guide treatment. We aimed to define prognostic subsets, assess the contribution of Modern-Imaging-Methods (MIMs; 18F-FDG-PET/CT or WB-MRI) to LAT selection, and describe progression after first-line therapy in these subgroups of patients. Materials and Methods: All consecutive patients with HR+/HER2− OMBC treated at our institution between 2012 and 2020 were included. OMBC was defined as ≤5 metastases. Prognostic factors, including biological subtype, anatomical distribution, imaging modality, and LAT, were evaluated for overall and progression-free survival (OS, PFS). Results: Among 145 patients (median follow-up 82.8 months), median OS and PFS were, respectively, 81.1 and 26.5 months. Luminal-A-like subtypes, absence of liver metastases, and use of MIMs independently predicted better survival. LAT improved PFS (hazard ratio [HR] = 0.52; 95% CI: 0.29-0.91, P = .0233) and showed a trend toward longer OS. In patients staged with MIMs, LAT significantly improved both OS (HR = 0.29; 95% CI: 0.12-0.73, P = .008) and PFS (HR = 0.40; 95% CI: 0.21-0.77, P = .0064). After first-line systemic therapy, only 18% developed polymetastatic progression. Conclusion: In HR+/HER2− OMBC, 3 actionable considerations emerge: staging must incorporate modern imaging to accurately define metastatic burden; LAT may be considered in selected patients with low-grade disease, absence of liver metastases, and long disease-free interval; in oligoprogression after first-line therapy, LAT should be re-evaluated within a multidisciplinary setting. These data offer pragmatic benchmarks to individualize treatment while awaiting definitive randomized evidence.
- 25 January 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 181, 109486
Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis
- 25 January 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 181, 109486
Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis
- 11 May 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 166 (1) , 8-17
The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer
- 11 May 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 166 (1) , 8-17
The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32 (6)
Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer
Angeles MA, et al. J Gynecol Oncol. 2021 Aug;32:e78. https://doi.org/10.3802/jgo.2021.32.e78
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32 (6)
Open AccessEffect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer
Angeles MA, et al. J Gynecol Oncol. 2021 Aug;32:e78. https://doi.org/10.3802/jgo.2021.32.e78
- 1 August 2019
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 45 (8) , 1410-1416
Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer
- 1 August 2019
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 45 (8) , 1410-1416
Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer